Please login to the form below

Not currently logged in
Email:
Password:

FDA approves once-daily HIV treatment Complera

The FDA approves Johnson&Johnson/Gilead’s once daily, single tablet regime HIV-1 treatment, Complera

The US Food and Drug Administration (FDA) has approved Complera, a once-daily HIV treatment.

Complera is for the treatment of HIV-1 infection in treatment-naive adults, and works through combining Johnson & Johnson and Tibotec's Edurant (rilpivirine) and Gilead's Truvada (tenofovir/emtricitabine).

FDA approval was granted due to data gained from the late-stage ECHO and THRIVE studies. A bioequivalence study demonstrated that when compared to tenofovir and emtricitabine and rilpivirine, Complera achieved the same levels of medication in the blood.

Complera is expected to generate around $567m in revenue in 2013 according to Lazard Capital Markets analyst Joel Sendek, who referred to the drug as a “catalyst”.

Complera is the “second complete antiretroviral treatment for HIV-1”, that is available in a single tablet regimen.

11th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics